Patrick G Harran

US Patent:

7309792, Dec 18, 2007

Filed:

Mar 1, 2005

Appl. No.:

11/070733

Inventors:

Patrick G. Harran - Dallas TX, US
Xiaodong Wang - Dallas TX, US
Jef K. De Brabander - Dallas TX, US
Lin Li - Dallas TX, US
Ranny Mathew Thomas - Dallas TX, US
Hidetaka Suzuki - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07D 249/04
C07D 257/04
A61K 31/41
A61K 31/42

US Classification:

548237, 548251, 548252, 548253, 548255, 514359, 514374, 514381, 514616, 564153

Abstract:

Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.

US Patent:

7517895, Apr 14, 2009

Filed:

Oct 31, 2005

Appl. No.:

11/264502

Inventors:

Patrick G. Harran - Dallas TX, US
Jing Li - Dallas TX, US
Susan Jeong - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61P 35/00
A61K 31/425
C07D 291/00

US Classification:

514366, 514375, 540457

Abstract:

The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds.

US Patent:

7538129, May 26, 2009

Filed:

Oct 31, 2006

Appl. No.:

11/591016

Inventors:

Patrick G. Harran - Dallas TX, US
Noelle Williams - Dallas TX, US
Anthony Burgett - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61P 35/00
A61K 31/425
C07D 291/00

US Classification:

514366, 514375, 540457

Abstract:

A specific diazonamide A analog and its salts and conjugates are effective in treating proliferative diseases.

US Patent:

7622289, Nov 24, 2009

Filed:

Jun 12, 2006

Appl. No.:

11/451926

Inventors:

Patrick Harran - Dallas TX, US
Xiaodong Wang - Dallas TX, US
Gelin Wang - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C12N 9/10
C12N 15/00
C12Q 1/00
C12Q 1/48
G01N 33/53
A61K 38/51
A01N 25/00
C12P 21/04

US Classification:

435193, 435 4, 435 71, 435 15, 435 691, 435 711, 435440, 514789, 424 945

Abstract:

Ornithine δ-aminotransferase (OAT) facilitates microtubule assembly in addition to its aminotransferase activity in mitochondria. An N-terminal proteolysis of the first 17 amino acids of OAT block its transport to the mitochondria. The resultant truncated protein (OATC) forms specific complexes with mitotic spindle promoting proteins such as Eg5 and takes on a Ran-dependent spindle-assembly activity. Methods and compositions for inhibiting mitotic spindle assembly in a cell by specifically inhibiting OAT, and methods for screening for inhibitors of (1) the spindle-assembly function of OAT, (2) the protease that N-truncates OAT, (3) the OAT/RanGTP association and (4) the OAT/Eg5 association are disclosed.

US Patent:

7638544, Dec 29, 2009

Filed:

Dec 17, 2007

Appl. No.:

11/958365

Inventors:

Patrick G. Harran - Dallas TX, US
Xiaodong Wang - Dallas TX, US
Jef K. De Brabander - Dallas TX, US
Lin Li - Dallas TX, US
Ranny Mathew Thomas - Dallas TX, US
Hidetaka Suzuki - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 31/42

US Classification:

514374, 514359, 514381, 514616

Abstract:

Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.

US Patent:

7816538, Oct 19, 2010

Filed:

Jul 24, 2009

Appl. No.:

12/509190

Inventors:

Patrick G. Harran - Dallas TX, US
Xiaodong Wang - Dallas TX, US
Jef K. De Brabander - Dallas TX, US
Lin Li - Dallas TX, US
Ranny Mathew Thomas - Waltham MA, US
Hidetaka Suzuki - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07D 249/04
C07D 257/04
A61K 31/41
A61K 31/42

US Classification:

548237, 548251, 548252, 548253, 548255, 564153, 514359, 514374, 514381, 514616

Abstract:

Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.

US Patent:

7851620, Dec 14, 2010

Filed:

Jun 6, 2008

Appl. No.:

12/134984

Inventors:

Gunnar Hanson - Chapel Hill NC, US
Charles Caldwell - Dallas TX, US
Patrick G. Harran - Los Angeles CA, US
Susan Harran - Dallas TX, US
Qi Wei - Dallas TX, US
Ming Zhou - Coppell TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX
Joyant Pharmaceuticals, Inc. - Dallas TX

International Classification:

C07D 498/22
C07D 263/00
C07D 263/34

US Classification:

540456, 548236, 548218

Abstract:

This invention relates to novel macrocyclic lactams intermediates useful for the preparation of diazonamide analogs. This invention also relates to a novel electrochemical oxidative cyclization for the preparation of such macrocyclic lactams, and their further elucidation to provide diazonamide analogs.

US Patent:

7884211, Feb 8, 2011

Filed:

Jul 24, 2009

Appl. No.:

12/509218

Inventors:

Patrick G. Harran - Dallas TX, US
Xiaodong Wang - Dallas TX, US
Jef K. De Brabander - Dallas TX, US
Lin Li - Dallas TX, US
Ranny Mathew Thomas - Waltham MA, US
Hidetaka Suzuki - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07D 249/04
A61K 31/42

US Classification:

548237, 548251, 548252, 548253, 548255, 514359, 514374, 514381, 514616, 564153

Abstract:

Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.